Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use How To Buy information on the last page of this document.

**We look forward to being of service to you.**

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

**Phone:** +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com
Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Vernalis plc (Vernalis) is a pharmaceutical company, which focuses at developing novel pharmaceuticals for the treatment of several diseases. The product portfolio of the company comprises frovatriptan for the acute treatment of migraine; Tuzistra XR, which targets the US prescription cough cold market; and Moxatag, a once-a-day formulation of the antibiotic (amoxicillin), indicated for the treatment of tonsillitis and pharyngitis secondary to Streptococcus pyogenes. It also specializes in fragment and structure based drug discovery. The company has collaboration agreements with pharmaceutical companies, including Novartis, Endo, GSK, Genentech, Biogen Idec, AKP, Menarini, Lundbeck, Servier, Taisho and Tris. It has operations in Europe and North America. Vernalis is headquartered in Winnersh, the UK.

Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of
the company.

- Key Competitors - A list of the key competitors of the company.

- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Additional Details

Publisher : Global Data
Reference : GDPH40875D
Number of Pages : 41
Report Format : PDF
Publisher Information : 
Table Of Contents for Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 11-12-2018]

- Table of Contents
- List of Figures
- List of Tables
- Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
- Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
- Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018
- Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018
- Vernalis Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018
- Vernalis Plc, Pharmaceuticals & Healthcare, Deal Details
  - Asset Purchase
    - Vernalis Acquires US rights to MOXATAG from Pragma Pharma
  - Partnerships
    - Vernalis and Daiichi Sankyo Enter into Agreement
    - Vernalis and Servier Enter into Discovery Agreement
    - Vernalis Enters into Research Agreement with Taisho Pharma
    - Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei
    - Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier
    - Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies
  - Licensing Agreements
    - Corvus Pharma Amends Licensing Agreement With Vernalis
    - CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat
    - Vernalis Enters into Licensing Agreement with RedoxTherapies
  - Equity Offering
    - Vernalis Raises USD58 Million in Private Placement of Shares
  - Private Placement Of Ordinary Shares For US$31 Million
  - Vernalis Completes Public Offering Of Ordinary Shares For US$77.7 Million
  - Acquisition
    - Ligand Pharma Acquires Vernalis
  - Vernalis Plc - Key Competitors
  - Vernalis Plc - Key Employees
  - Vernalis Plc - Locations And Subsidiaries
  - Recent Developments
    - Vernalis Reports Unaudited Interim Results For The Six Months Ended 31 December 2017
    - Vernalis: Results Announcement for the year ended 30 June 2017
    - Vernalis: Year-End Trading Update and Notice of Full Year Results
  - Financial Announcements
    - Mar 28, 2018: Vernalis Reports Unaudited Interim Results for the six months ended 31 December 2016
    - Jul 18, 2017: Vernalis: Year-End Trading Update and Notice of Full Year Results
  - Corporate Communications
    - Aug 16, 2018: Vernalis announces changes in board
  - Product News
    - 04/05/2017: Drug makes head-and-neck cancer more sensitive to radiotherapy
  - Significant Developments
- Appendix
  - Methodology
  - About GlobalData
List Of Tables in Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 11-12-2018]

List of Tables

Vernalis Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vernalis Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vernalis Plc, Deals By Therapy Area, 2012 to YTD 2018 8
Vernalis Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vernalis Acquires US rights to MOXATAG from Pragma Pharma 10
Vernalis and Daiichi Sankyo Enter into Agreement 11
Vernalis and Servier Enter into Discovery Agreement 12
Vernalis Enters into Research Agreement with Taisho Pharma 13
Vernalis Enters Into Drug Discovery Agreement With Asahi Kasei 14
Vernalis Enters Into Co-Development Agreement With Les Laboratoires Servier 15
Vernalis Enters Into Drug Discovery Agreement With Genentech To Develop Therapies 16
Corvus Pharma Amends Licensing Agreement With Vernalis 17
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 18
Vernalis Enters into Licensing Agreement with RedoxTherapies 19
Vernalis Raises USD58 Million in Private Placement of Shares 20
Vernalis Completes Private Placement Of Ordinary Shares For US$31 Million 21
Vernalis Completes Public Offering Of Ordinary Shares For US$77.7 Million 22
Ligand Pharma Acquires Vernalis 23
Vernalis Plc, Key Competitors 25
Vernalis Plc, Key Employees 26
Vernalis Plc, Subsidiaries 27
List Of Figures, Charts and Diagrams in Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 11-12-2018]

List of Figures

Vernalis Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vernalis Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vernalis Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
How to Buy...

Vernalis Plc (VER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 11-12-2018]

Option 1 - Online
Go to our website and pay online with any major debit or credit card:
https://www.bioportfolio.co.uk/product/228321

Option 2 - Request a Proforma Invoice
Fill in the details below, and either Scan this page and email it to us at reportstore@bioportfolio.com or Fax it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name: .................................................................................................................................
Job Title: ...........................................................................................................................................
Your Email: ........................................................................................................................................
Your Contact Phone: ...........................................................................................................................
Company Name: .................................................................................................................................
Address: ............................................................................................................................................
Post/Zip Code: .................................................................................................................................
Country: ............................................................................................................................................
P.O. Number: ....................................................................................................................................
Any Other Instructions: .......................................................................................................................  

Pricing Options: (please tick one)
- $250 | Single User Price
- $500 | Site License Price
- $750 | Global License Price

Payment Options: (please tick one)
- Online Credit Card (we will email you the invoice with a payment link)
- Direct Wire Transfer (we will email you the invoice with our bank details)

Authorising Signature: .....................................................................................................................

Option 3 - Phone Us on +44 (0)1300 321501
We will be delighted to give you our personal attention.